02/14/2025 1:35 PM | Agios Pharmaceuticals (Subject) BB BIOTECH AG (Filed by)
| Form SCHEDULE 13G/A | |
02/13/2025 8:26 AM | Agios Pharmaceuticals (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
02/13/2025 5:32 AM | Agios Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/13/2025 5:01 AM | Agios Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/04/2025 11:02 AM | Agios Pharmaceuticals (Subject) Farallon Capital Partners, L.P. (Filed by)
| Form SCHEDULE 13G/A | |
01/13/2025 6:01 AM | Agios Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/07/2025 4:05 PM | Agios Pharmaceuticals (Issuer) Milanova Tsveta (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/06/2025 5:36 AM | Agios Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/13/2024 3:14 PM | Agios Pharmaceuticals (Issuer) Washburn Theodore James Jr. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/08/2024 3:17 PM | Agios Pharmaceuticals (Subject) Ballal Rahul D. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/08/2024 1:40 PM | Agios Pharmaceuticals (Subject) Farallon Capital Partners, L.P. (Filed by)
| Form SC 13G/A | |
Get the Latest News and Ratings for AGIO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
|
10/31/2024 8:20 AM | Agios Pharmaceuticals (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
10/31/2024 5:56 AM | Agios Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
09/30/2024 3:15 PM | Agios Pharmaceuticals (Issuer) Jones Cecilia (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/13/2024 3:12 PM | Agios Pharmaceuticals (Issuer) Smith Cynthia (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/13/2024 3:15 PM | Agios Pharmaceuticals (Issuer) Ballal Rahul D. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/12/2024 4:15 PM | Agios Pharmaceuticals (Issuer) Goff Brian (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/01/2024 8:49 AM | Agios Pharmaceuticals (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
08/01/2024 6:03 AM | Agios Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
07/03/2024 3:30 PM | Agios Pharmaceuticals (Issuer) Gheuens Sarah (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/20/2024 4:06 PM | Agios Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/17/2024 4:29 PM | Agios Pharmaceuticals (Issuer) Schenkein David P (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/17/2024 4:31 PM | Agios Pharmaceuticals (Issuer) FOUSE JACQUALYN A (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/17/2024 4:32 PM | Agios Pharmaceuticals (Issuer) Foster-Cheek Kaye I (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/17/2024 4:13 PM | Agios Pharmaceuticals (Issuer) CAPELLO JEFFREY D (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/17/2024 4:15 PM | Agios Pharmaceuticals (Issuer) Owen Catherine E. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/17/2024 4:18 PM | Agios Pharmaceuticals (Issuer) Scadden David (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/17/2024 4:19 PM | Agios Pharmaceuticals (Issuer) Ho Maykin (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/17/2024 4:20 PM | Agios Pharmaceuticals (Issuer) Smith Cynthia (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/17/2024 4:22 PM | Agios Pharmaceuticals (Issuer) Ballal Rahul D. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/05/2024 6:50 PM | Agios Pharmaceuticals (Subject) Goff Brian (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/05/2024 3:14 PM | Agios Pharmaceuticals (Issuer) Washburn Theodore James Jr. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/28/2024 6:09 AM | Agios Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/02/2024 8:20 AM | Agios Pharmaceuticals (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
05/02/2024 6:01 AM | Agios Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/10/2024 3:03 PM | Agios Pharmaceuticals (Issuer) FOUSE JACQUALYN A (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/07/2024 5:47 PM | Agios Pharmaceuticals (Issuer) Washburn Theodore James Jr. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/07/2024 5:49 PM | Agios Pharmaceuticals (Issuer) Foster-Cheek Kaye I (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/07/2024 3:26 PM | Agios Pharmaceuticals (Subject) Foster-Cheek Kaye I (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/06/2024 5:05 PM | Agios Pharmaceuticals (Subject) Foster-Cheek Kaye I (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/05/2024 6:06 PM | Agios Pharmaceuticals (Subject) Foster-Cheek Kaye I (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Collect $7k per month from Tesla’s SECRET dividend (Ad) There's a little-known secret about Tesla that even seasoned investors don't know.
Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month.
This backdoor strategy is changing the game for smart investors.
Want to see how it works? Click here to uncover Tesla's hidden income secret. |
02/26/2024 8:21 PM | Agios Pharmaceuticals (Subject) Schenkein David P (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/22/2024 4:43 PM | Agios Pharmaceuticals (Issuer) Washburn Theodore James Jr. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |